Global Organ and Tissue Transplantation and Alternatives Market to 2024 - Impact Analysis of COVID-19
Dublin, Jan. 06, 2021 (GLOBE NEWSWIRE) -- The "Organ and Tissue Transplantation and Alternatives" report has been added to ResearchAndMarkets.com's offering.
This report offers forecasts, by product segment, from 2018 through 2024, including supporting analyses for projections. Product segments covered consist of the solid organ (e.g., kidneys, liver, heart-lung, pancreas, intestines) and the tissue transplantation (e.g., bone, skin, cornea, heart valve) markets, along with the pharmaceuticals that accompany each market.
Also included are experimental xenografts and artificial organs; tissue transplants; and cell transplants (e.g., bone marrow, cord blood, peripheral blood, islet cell). The report touches on the use of fetal cells, stem cells, and altered cancer cells.
The arrangement of this report offers an overview of the key elements in the transplantation process: tissue typing, procurement and preservation, immunosuppressants for solid organ and tissue transplants, and postoperative monitoring. International markets are discussed, and information is provided on industry structure and the regulatory environment.
Within each section are discussions of commercialization opportunities for each segment of the market. New or emerging devices, techniques, and pharmaceuticals are highlighted.
Profiles of leading companies involved with solid organ transplantation, tissue transplantation, and alternative technologies are included. The report provides information on company placement within the market and strategic analyses of the companies' available and emerging products.
An appendix featuring various terms and processes used in transplantation is provided at the end of the report.
This report cites autologous products only in relation to their impact on the market for allografts. It does not include blood products, except for peripheral and umbilical cord blood as a source of stem cells.
By geography, the market has been segmented into North America, Europe, Asia-Pacific, and Rest of the World regions. Detailed analysis of the market in major countries such as the U.S., Germany, the U.K., Italy, France, Spain, Japan, China, India, Brazil, Mexico, GCC countries, and South Africa will be covered in the regional segment. For market estimates, data will be provided for 2019 as the base year, with estimates for 2020 and forecast value for 2024.
Report Includes:
26 data tables and 37 additional tables
An overview of the global organ and tissue transplantation and alternatives market
Estimation of the market size and analyses of market trends, with data from 2018 to 2019, estimates for 2020, and projection of CAGR through 2024
Details about organ and tissue transplantation and alternatives, their pathophysiology and effects, and major advancement and latest trends
A look at the regulatory scenarios and initiatives by a government organization
Analysis of current and future market dynamics and identification of key drivers, restraints, and opportunities such as increasing incidence of organ donations, improved awareness about organ donations, side effects of organ and tissue transplantation, and antibiotic resistance infections
Coverage of emerging procedures and products in development and discussion on the prevalence of major chronic diseases which initiates organ damage or donation
Discussion on the role of the organ procurement organization and information on transplantation process and preparation and coverage of issues like black market donors
Impact analysis of COVID-19 on organ and tissue transplantation and alternatives market
Market share analysis of the key companies of the industry and coverage of events like mergers & acquisitions, joint ventures, collaborations or partnerships, and other key market strategies
Company profiles of major players of the industry, including Abiomed Inc., Bayer AG, F. Hoffmann-La Roche & Co., Johnson & Johnson, Novartis AG, Pfizer Inc., and XVIVO Perfusion
Growth of the global market is attributed to factors such as the growing prevalence of obesity, diabetes, cancer, and other chronic diseases which leads to organ damage, a strong product regulatory scenario, and strong investment in research and development activities by key market players including Abbott Laboratories, Cryolife Inc., Bristol-Myers Squibb, Novartis Ag, F. Hoffmann-La Roche Ltd., Medtronic, Arthrex Inc., Depuy Synthes (Johnson & Johnson), and Allosource.
Although various factors facilitate the global market for organ and tissue transplantation and alternatives, certain parameters such as challenges in HLA sequencing and gaps in supply and demand can constrain market growth. For instance, although there is an increasing need for organ transplants, the shortage of organs worldwide limits the number of transplant procedures performed, and in turn, creates an impact on transplant diagnostics procedures. An increasing number of candidates on the waiting list for organ transplant procedures worldwide further widens this gap of availability and requirement of organs for transplant purposes.
Successful organ and tissue transplantation began to arrive in the mid-1970s when tissue typing coupled with the use of cyclosporine provided more successful graft and patient survival. Today, patient and graft survival for kidney transplants is higher than 90% for the first year post-transplant, and often the success rate is 80% to 90% for five years post-transplant, with some recipients living more than 20 years after their transplant.
Continuing developments in organ procurement, organ preservation, tissue typing, and immunosuppressant use have bolstered successful transplantation surgical techniques. Evolving posttransplant drug and testing regimens have added to the success rate with close post-transplant monitoring and immunosuppressant dosage review.
Key Topics Covered:
Chapter 1 Introduction
Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
Information Sources
Methodology
Geographic Breakdown
Analyst's Credentials
Custom Research
Related Reports
Chapter 2 Summary and Highlights
Chapter 3 Market and Technology Background
Organ and Tissue Transplantation and Alternatives
Cost of Care
Solid Organ Preservation
Immunosuppression
Organ Transplantation Alternatives
Trends in Organ and Tissue Transplantation Techniques and Their Alternatives
3D Tissue Assembly
Nanotechnology for Tissue Regeneration
Innovation by Small Firms
Chapter 4 Market Dynamics
Market Drivers
Increasing Epidemiology of Different Diseases Influencing Organ Transplantations
Rise in the Geriatric Population
Rising Awareness of Importance of Organ and Tissue Donation
New Therapeutic Pathways for Organ Transplantation and Their Alternatives
Market Restraints
Challenges in Human Leukocyte Antigen (HLA) Sequencing
Demand and Supply Gap
Market Opportunities
Growing Economic Benefits of Organ and Tissue Transplants
Improvement in Healthcare Infrastructure
Chapter 5 Market Breakdown by Product & Devices
Global Market for Organ and Tissue Transplantation and Alternatives
Alternative Technologies
Market Size and Forecast
Alternatives to Heart Transplantation
Surgical
Mechanical
Total Artificial Heart
Ventricular Assist Devices (VADs)
Generations of Designs
Orthopedic Alternatives
Tissue Products
Market Size and Forecast
Immunosuppressants
Market Size and Forecast
Solid Organ Preservation Solutions
Market Size and Forecast
Preservation Solutions in Development
Tissue Typing
Market Size and Forecast
Chapter 6 Market Breakdown by Region
Global Market for Organ and Tissue Transplantation and Alternatives by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
India
Australia and New Zealand
Rest of Asia-Pacific
Rest of the World
Market Analysis
Brazil
South Africa
Rest of the World Countries
Chapter 7 Impact of COVID-19
Introduction
Impact on Kidney Transplant Program
Impact on Pharmaceutical Companies
Donor Testing
COVID-19 in Transplant Recipients
Minimizing Infection Risk in Recipients
Future Perspectives
Chapter 8 Overview of Donation Process
Introduction
Black Market Donors
The Transplantation Process
Cost of Solid Organ Transplantation in the U.S.
Chapter 9 Regulations & Reimbursement
Regulations in the U.S.
U.S. Federal Regulation of Human Tissue
History of Regulation in the U.S.
Regulations Outside the U.S.
Reimbursement in the U.S.
Organ Acquisition Costs
Reimbursement for Hospital Costs
Reimbursement for Physician Services
Reimbursement for Immunosuppressants in the U.S.
Reimbursement Outside the U.S.
Treatment in EU Countries
Chapter 10 Competitive Landscape
Global Company Ranking Analysis
Mergers and Acquisitions
Agreements, Launches, Collaborations, and Partnerships
Chapter 11 Company Profiles
Abiomed Inc.
Abbvie Inc.
Amgen Inc.
Astrazeneca
Bayer Ag
Bristol-Myers Squibb
Caredx Inc.
F. Hoffmann-La Roche Ltd.
Johnson & Johnson
Mylan N.V.
Novartis Ag
Pfizer Inc.
Transmedics Inc.
Vertex Pharmaceuticals Inc.
Xvivo Perfusion
Chapter 12 Appendix: Acronyms
For more information about this report visit https://www.researchandmarkets.com/r/dq9l93
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900